Pharmamarketeer

Regeneron Pharma receives US FDA approval for Eylea injection to treat diabetic retinopathy

Regeneron Pharmaceuticals, Inc announced that the US Food and Drug Administration (FDA) has approved Eylea (aflibercept) injection to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness.

Medhc-fases-banner
Advertentie(s)